Daybue(Trofinetide)

Daybue is for the treatment of Rett syndrome in adults and pediatric patients aged 2 and above.

Recommended Dosage and Administration

Dosage: Twice daily, morning and evening, determined by patient weight.

Administration: Can be taken with or without food.

Patient Weight and Corresponding Dosage:

• 9 kg to less than 12 kg: 5,000 mg twice daily (25 mL twice daily)
  
• 12 kg to less than 20 kg: 6,000 mg twice daily (30 mL twice daily)
  
• 20 kg to less than 35 kg: 8,000 mg twice daily (40 mL twice daily)
  
• 35 kg to less than 50 kg: 10,000 mg twice daily (50 mL twice daily)
  
• 50 kg or more: 12,000 mg twice daily (60 mL twice daily)
  

Administration Options: Can be taken orally or through a gastrostomy (G) tube. Gastrojejunal (GJ) tube doses must be administered through the G-port.

• Diarrhea: Most patients may experience diarrhea while on Daybue. Prior to starting Daybue , patients should cease laxative use. If diarrhea occurs, patients should begin antidiarrheal treatment, increase fluid intake, and notify their healthcare provider. If severe diarrhea or dehydration is suspected, consider interrupting, reducing the dose, or discontinuing Daybue .
• Weight Loss: Some patients may experience weight loss. Monitor weight and consider interrupting, reducing the dose, or discontinuing Daybue if significant weight loss occurs.

Adverse Reactions

The most common adverse reactions (reported in at least 10% of Daybue-treated patients and at least 2% more frequently than in the placebo group) are diarrhea and vomiting.

Drug Interactions

• For orally administered CYP3A4 sensitive substrates, monitor closely for adverse reactions when used concomitantly.
• Avoid concomitant use with OATP1B1 and OATP1B3 substrates for which small changes in substrate plasma concentration may lead to serious toxicities.

What documents are required to import Daybue (Trofinetide) to India?

Daybue (Trofinetide) solution can be imported by patients or government hospitals on the name of the patients only. 

The following documentation is required to import the product:

• A valid prescription from a qualified doctor.
  
• Patients diagnostic reports
  
• Patients ID proof (issued by the government of India)

The order will be confirmed only after the receipt of:

• A valid prescription from Doctor
  
• Import permit if applicable

Daybue (Trofinetide) solution is a (prescription drug, prescription medication, or prescription medicine) pharmaceutical drug that legally requires a medical prescription to be dispensed.

IPN (Indian Pharma Network) helps import cancer medicines on the named patient supply (NPS). Indian Pharma Network is the facilitator providing input

Please contact +91-9310090915 | Toll-Free Number: 1800-889-1064 or write us at info@indianpharmanetwork.in for Daybue price in India. 

We take to guarantee quality and delivery anywhere in the world as per the buyer’s requirements.

Daybue (Trofinetide) can be obtained via Indian Pharma Network, which also has the capacity to supply it. Customers of Indian Pharma Network have access to the greatest medical care accessible anywhere in the world.

Is Daybue approved by the FDA?

Yes, it is approved by FDA in 2023

What is the mechanism of action of Daybue?

A novel synthetic analogue of the amino-terminal tripeptide of IGF-1 called Daybue (trofinetide) is intended to treat the main symptoms of Rett syndrome by perhaps lowering neuroinflammation and promoting synaptic function.

What is Daybue used for?

Daybue is primarily used for the treatment of Rett syndrome, a rare and severe neurological disorder that primarily affects girls and women. It helps alleviate some of the symptoms associated with this condition.

How is Daybue administered?

Daybue is available in oral solution form and is typically administered twice daily, in the morning and evening. 

What are the common side effects of Daybue?

Common side effects of Daybue may include diarrhea and vomiting. Weight loss is another potential side effect.